Nasal vaccine opportunity Vivaldi’s focus on intranasal, self-adjuvanting Delta NS1 platform for respiratory viruses presents a ready-made gateway for partnerships with contract manufacturers, distributors, and healthcare providers seeking non-invasive vaccine options with rapid protection profiles.

Influenza portfolio DeltaFLU and Delta NS1 based vaccines position the company in universal influenza solutions, creating cross-sell potential with established influenza vaccine suppliers, health systems, and public health programs aiming to broaden protection across strains.

Clinical-stage traction Phase 2 status for DeltaFLU and ongoing clinical development for Delta-19 signal near-term collaboration windows with CROs, clinical trial site networks, and investors seeking opportunities in rapidly advancing respiratory vaccine programs.

Strategic collaborations Active participation in industry events and a focus on intranasal delivery open avenues for partnerships with big biotech peers, CDMOs, and platform licensors looking to augment nasal vaccine capabilities and accelerate go-to-market timelines.

Financial and growth potential With multi-million revenue and modest funding, Vivaldi could leverage partnerships for manufacturing scale, distribution, and co-development deals to expand capacity, de-risk clinical timelines, and expand access in diverse markets.